How many insider trades does FilingIQ track for AVDL?

FilingIQ tracks 311 Form 4 insider transactions for AVDL (AVADEL PHARMACEUTICALS PLC), covering filings from Jan 3, 2017 onwards. 0 of those were filed in the last 90 days.

Are AVDL insiders net buyers or net sellers?

Across the full Form 4 history for AVDL, 68 transactions (22%) were open-market purchases and 13 (4%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does AVDL insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is AVDL in?

AVADEL PHARMACEUTICALS PLC (AVDL) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $2.12B.

AVDL insider trading

NasdaqGM Healthcare

AVADEL PHARMACEUTICALS PLC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

311

Last 90 days

Buys / sells

22% / 4%

Market cap

$2.12B

About AVADEL PHARMACEUTICALS PLC

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.

Company website: www.avadel.com

AVDL insider activity at a glance

FilingIQ has scored 311 insider transactions for AVDL since Jan 3, 2017. The most recent filing in our index is dated Feb 13, 2026.

Across the full history, 68 open-market purchases and 13 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on AVDL insider trades is 57.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live AVDL trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding AVDL

COWEN AND COMPANY, LLC

$23.19M · 1.5% of AUM

Samsara BioCapital, LLC

$12.91M · 2.7% of AUM

Frequently asked

How many insider trades does FilingIQ track for AVDL?: FilingIQ tracks 311 Form 4 insider transactions for AVDL (AVADEL PHARMACEUTICALS PLC), covering filings from Jan 3, 2017 onwards. 0 of those were filed in the last 90 days.
Are AVDL insiders net buyers or net sellers?: Across the full Form 4 history for AVDL, 68 transactions (22%) were open-market purchases and 13 (4%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does AVDL insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is AVDL in?: AVADEL PHARMACEUTICALS PLC (AVDL) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $2.12B.

Methodology & sources

Every AVDL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.